Co-oximetry
[Co-oximetry ]
EPTIS factsheet 142512 | Last revision 2024-05-21 | URL: https://www.eptis.bam.de/pts142512 https://www.eptis.bam.de/pts142512
| PT provider | ||||||||||||||||
| PT provider | Weqas Weqas | |||||||||||||||
| Based in | United Kingdom | |||||||||||||||
| Language(s) | ||||||||||||||||
| Remarks | The material is a blood-based matrix containing the 4 major haemoglobin derivates and unlike dyes provided by other EQA providers has equivalent spectral properties to whole blood. Compatible with all major Co-oximeters. Panel covers clinically relevant ranges. Packaged in an easy to use dual-chambered vial that separates the oxyhemoglobin from methemoglobin to enhance stability. Three aqueous samples are distributed monthly, with a minimum of 33 samples distributed over the year covering a wide clinically relevant range. The samples consist of a panel of 6 linearly related samples distributed on a number of occasions over that period which are used to assess both laboratory and method performance, including linearity, bias, within and between batch imprecision. Key Features: - Panel covers clinically relevant range. - Easy to use vials with minimal preparation time. - Material contains the 4 major haemoglobin derivates and unlike dyes has equivalent spectral properties to whole blood. - Compatible with all major Cooximeters. For more information: https://www.weqas.com/services/eqa/Co-oximetry/ or contact@weqas.com | |||||||||||||||
| Keywords | ||||||||||||||||
| Product groups |
Health care / medical devices
|
|||||||||||||||
| Testing fields |
Medical analysis
|
|||||||||||||||
| Technical details | ||||||||||||||||
|
||||||||||||||||
| Aims of the PT scheme | ||||||||||||||||
| Target group of participants | The Programme is available to both Laboratory and Point of Care testing sites. The Programme aims to assess the performance of organisations utilising blood gas analysers for the analysis of the patients’ haemoglobin and co-oximetry status. | |||||||||||||||
| Linked to specific legislation / standards | Accreditation by UKAS on the basis of ISO/IEC 17043 | |||||||||||||||
| Additional, subsidiary aims | validation of testing methods | |||||||||||||||
| Number of participants | ||||||||||||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043 |
|||||||||||||||
| Operation is commissioned / requested by | ||||||||||||||||
| Fees and frequency | ||||||||||||||||
| Participation fee | Fee dependent on number of participating sections and proximetry of testing methods. | |||||||||||||||
| Regularly operated | Yes (Frequency: Monthly. Samples: 3 x 2.0mL) | |||||||||||||||
| Year of first operation | 1994 | |||||||||||||||
| Contact details of the PT provider | ||||||||||||||||
| Provider | Contact person | |||||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.